Clinical Dilemmas in Interventional Cardiology

Transcatheter Aortic Valve Replacement During Pregnancy

Robert Hodson, MD; Eric Kirker, MD; Jeffrey Swanson, MD; Craig Walsh, MD, MPH; Ethan C. Korngold, MD; Sarah Ramelli, MS

Transcatheter aortic valve replacement (TAVR) is an approved and widely accepted standard treatment for severe symptomatic aortic stenosis (AS) in high-risk surgical candidates. Severe symptomatic AS during pregnancy presents a difficult clinical challenge. A 22-year-old female patient presented to our service at 15 weeks’ gestation with congenital symptomatic AS. After a thoughtful heart team evaluation, TAVR was recommended to the patient and performed at 22 weeks’ gestation. The authors further explore and discuss the preprocedure planning and treatment decisions of this case. The heart team focused on the timing and special considerations needed to ensure the health and safety of the patient and fetus. With careful preprocedural planning, TAVR can be a low-risk treatment option during pregnancy and provide a reliable bridge to a healthy, term delivery.

Case Presentation

A 22-year-old pregnant female patient presented with severe symptomatic AS at 15 weeks’ gestation. The patient was 165 cm tall, weighed 74 kg with a body mass index of 27 kg/m² and body surface area of 1.84 m² at the time of presentation. The patient’s clinical history includes congenital bicuspid aortic valve disease, which required balloon aortic valvuloplasty (BAV) at the age of 9 years. Throughout young adulthood, she had been asymptomatic with high levels of activity. Her chief complaints on presentation were increased dizziness, dyspnea on exertion, and chest discomfort. Echocardiography demonstrated a normal ejection fraction, an aortic peak flow velocity of 4.04 m/s, an aortic valve mean gradient of 38.22 mm Hg, an aortic valve area of 1.0 cm², and mild-to-moderate aortic insufficiency (AI). The ascending aorta was mildly enlarged (3.9 cm). There was mild narrowing of periductal isthmus with no Doppler gradient (Figure 1; Table 1). Stress echocardiography testing showed moderate AI and below-average exercise capacity. The patient completed 8 to 9 metabolic equivalents of exercise. Echocardiography documented a mean resting aortic valve gradient of 56 mm Hg and a postexercise mean gradient of 78 mm Hg (Table 2). The difference in aortic valve mean gradients between the routine and stress echocardiograms can be attributed to the difference in time and location of the 2 tests.

Discussion

Treatment Options

Dr Hodson: Symptomatic valvular disease during pregnancy is an uncommon clinical dilemma in North America. Cardiovascular diseases affect 0.2% to 4% of all pregnancies, and untreated cardiac disease during pregnancy accounts for 10% to 15% of maternal mortalities. Congenital bicuspid aortic valve disease, one of the more common congenital heart defects, is known to affect 2% of the general population. Bicuspid aortic valve disease was initially considered a relative contraindication to TAVR procedures, but TAVR procedures are increasingly being performed successfully to treat this condition. Current guidelines are specific for the treatment of valvular heart disease before pregnancy, including counseling and medical management. However, in a pregnancy with class IIb cardiovascular disease with symptomatic AS where surgical intervention is recommended, little direction outside of monitoring and echocardiography examination requirements is provided.

Bicuspid aortic valve disease is often associated with dilatation of the ascending aorta. The current evidence supports that hemodynamic wall stress in combination with an underlying connective tissue disorder or genetic abnormality of the ascending aortic media leads to bicuspid aortopathy. The expected pregnancy-related increase in heart rate, blood pressure, and stroke volume increases aortic wall stress leading to an increased risk of aortic dissection. Careful assessment of the ascending aorta is required in all patients with bicuspid disease because aortic dilatation may dictate surgical treatment. Aortic root enlargement >40 mm or an increase in aortic root size during pregnancy seem to be risk factors for type A dissection. Dr Walsh, you first saw this patient and ultimately referred her to the heart team. Can you share your thoughts about treatment options and the discussion with the patient, family, and the patient’s perinatologists?

Dr Walsh: Yes, the patient’s presentation highlights several important issues about management. Conservative medical management is the first-line therapy in asymptomatic patients. However, the benefits of medical management are limited for symptomatic patients and consist primarily of diuretic treatment. It is well validated that symptomatic stenotic valvular lesions are poorly tolerated during pregnancy and are associated with a high risk of complications and death during delivery. Table 3 shows the classification for maternal and fetal risks according to valvular heart lesions as outlined by Reimold and Rutherford. Severe AS with or without symptoms is classified as high risk for both the mother and the fetus. The World Health Organization classifications for maternal cardiovascular risk, first reported by Thorne et al, are as follows:

Maternal Risk Category

I - No cardiac disease
II - Mild cardiac disease
IIA - Moderate cardiac disease
IIB - Significant cardiac disease
III - High-risk cardiac disease
are shown in Table 4. Additionally, Thorne et al\textsuperscript{12,20} was the first to apply symptoms to the World Health Organization risk classifications (Table 5) and state that AS (asymptomatic or symptomatic) is a class IV maternal risk with pregnancy being contraindicated.

Because of our patient’s symptoms, echocardiographic findings, and stress test results, a conservative management strategy was deemed high risk for both the mother and fetus\textsuperscript{21}, and surgical interventions were recommended as a lower risk treatment strategy compared with medical management\textsuperscript{22,23}.

**Dr Hodson**: Dr Swanson, what are the surgical considerations for an aortic valve replacement during pregnancy?

**Dr Swanson**: Surgical aortic valve replacement (SAVR) during pregnancy does pose an increased but acceptable risk to the mother. However, SAVR presents a much higher risk to the fetus. The estimated risk of fetal demise during SAVR is \( \approx 20\% \).\textsuperscript{24} The surgical literature is sparse, with more reported cases from developing countries, in the arena of cardiopulmonary bypass surgery during pregnancy. A literature review of 69 published reports between 1958 and 1992 of cardiopulmonary bypass surgery during pregnancy reported an overall maternal mortality rate of 2.9\% and embryo-fetal mortality rate of 20.2\% with the mortality and morbidity being lower in the later cases.\textsuperscript{25} The neonatal–fetal mortality rate was later reported at 29\% when cardiopulmonary bypass surgery was performed during pregnancy,\textsuperscript{3} whereas a 2014 review of 23 emergency or urgent cardiopulmonary bypass surgery during pregnancy in Cairo report 14 fetus losses.\textsuperscript{26}

After discussion with the patient and family, SAVR was not selected because of the unacceptably high risk to the fetus.

**Dr Hodson**: Dr Korngold, please summarize the team discussion about treatment with BAV.

**Dr Korngold**: We considered repeating BAV as it is a viable treatment option for AS in pregnant women.\textsuperscript{27,28} BAV has an overall lower associated risk of complication compared with TAVR procedures.\textsuperscript{29} Serial BAV procedures have been reported to increase AI in 2.1\% of patients in one study.\textsuperscript{30} In our patient’s case, we were concerned about several issues, including the uncertain reduction in AS gradient, the existing degree of moderate AI, and the uncertain duration of BAV benefit. For these reasons and importantly because of the patient’s existing AI, BAV was deemed by the heart team as an unreliable treatment option. Although TAVR during pregnancy has not been studied, the existing data suggested that TAVR performed during pregnancy would likely be successful with a lower risk to the fetus and acceptable maternal risk compared with SAVR.\textsuperscript{31} The risk associated with TAVR are well studied in high-risk, inoperable,\textsuperscript{1} and intermediate-risk groups.\textsuperscript{32} We do not know the risk of TAVR in young healthy populations with bicuspid disease.

**Procedural Considerations and Planning**

**Dr Kirker**: When our patient first presented, we searched the literature for guidance and found no published TAVR during pregnancy cases. Therefore, a heart team evaluation was critical. The heart team included perinatologists, radiation experts, and other experts to assist with the evaluation, planning, and execution of this procedure. A successful procedure was defined preoperatively as a valve implantation that adequately bridged the patient and fetus to a healthy delivery.

**Dr Walsh**: In our discussions with the perinatologist, it was emphasized that timing was critical to the success of the

---

**Table 1. Summary of Presentation Transthoracic Echo Data**

<table>
<thead>
<tr>
<th>Ejection fraction</th>
<th>65% to 70%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic peak flow velocity</td>
<td>4.04 m/s</td>
</tr>
<tr>
<td>Aortic valve peak gradient</td>
<td>65.39 mmHg</td>
</tr>
<tr>
<td>Aortic valve mean gradient</td>
<td>38.22 mmHg</td>
</tr>
<tr>
<td>Aortic valve area</td>
<td>1.0 cm²</td>
</tr>
<tr>
<td>Aortic regurgitation, pressure half-time</td>
<td>433 ms</td>
</tr>
</tbody>
</table>
procedure and the health of the mother and fetus. Consideration was given to fetal viability in the event of premature delivery. Delaying treatment until after 28 weeks’ gestation when survival of the fetus would be possible was discussed. The perinatologists recommended prompt treatment to decrease risks of complications caused by delay. The optimal time for a cardiac procedure during pregnancy is considered to be early in the second trimester. Therefore, the procedure was scheduled for 22 weeks’ gestation.

Dr Hodson: Management of radiation exposure to the fetus and mother were of prime concern. Fetal exposure to radiation can cause miscarriage, growth retardation, mental retardation, major malformations, and IQ reduction. At 22 weeks’ gestation, acute radiation doses of ≤500 mGy are not associated with noncancerous health effects for the pregnancy or the fetus. Radiation doses of <500 mGy have an estimated childhood cancer incidence rate of ≤6% for all gestational ages. Computed tomographic angiography (CTA) is the gold standard for pre-TAVR imaging, but CTA is not recommended during pregnancy. There is an increased awareness and concern about radiation exposure and lifetime breast cancer risk in women with metabolically active breast tissue during and after pregnancy. Parker et al has shown that computed tomographic pulmonary angiography exposes the breasts of an average-sized woman to a radiation dose of 2.0 to 5.0 rad (20–50 mGy), which is roughly equivalent to 10 to 25 two-view mammograms and up to as many as 100 to 400 chest radiographs. If CTA is performed during pregnancy, radiation exposure should be kept to a minimum with high-speed scanning and performed with appropriate shielding.

Dr Korngold, what additional options are there for imaging during pregnancy?

Dr Korngold: Transesophageal echocardiogram (TEE) is an alternative evaluation of the aortic annulus and aortic complex, and intravascular ultrasound (IVUS) can be used to visualize the vascular access. Three-dimensional (3D) TEE compared with CTA is well validated in the evaluation of the aortic complex and aortic annulus. Sagittal annulus diameters, coronal diameter, and annulus area in TAVR patients were seen to have a 77% agreement between 3D TEE and CTA measurements. We were able to obtain high-quality TEE images of the patient. Recommendations also state that fluoroscopy and cineangiography should be kept as brief as possible. After consulting with a radiation physicist and radiologists, IVUS, TEE, and fluoroscopy with fluoro saves only were planned as the imaging modalities to reduce radiation exposure. Radiation exposure would occur with fluoroscopy only during the TAVR procedure, and a dose well below 500 mGy was expected. Radiation exposure was not assigned a maximum amount as the patient and family’s main concern was for fetus survival.

Dr Walsh: Contrast administration is not approved during pregnancy. Contrast exposure to the fetus has not been researched sufficiently to confirm its effects on fetal abnormalities. However, gadolinium and iodinated contrast mediums have not been found to cause any mutagenic or teratogenic side effects. There is a theoretical concern that iodine may alter the development of the fetal thyroid if given to a pregnant woman. The contrast media safety committee of European Society of Urogenital Radiology has approved the use of both iodinated and gadolinium contrast media for use during pregnancy. To minimize the risk, contrast administration was planned to be used only for aortic root angiography during the TAVR procedure.

Heparin is safe during pregnancy because it does not cross the placenta and is used during pregnancy when anticoagulation is required. Heparin would be administered during and after the procedure for prevention of thromboembolism. Low-dose aspirin (80–100 mg/d) is considered safe during pregnancy and would be administered postoperatively. High-dose aspirin is not recommended because of risk of fetal bleeding, congenital defects, and loss of pregnancy.

<table>
<thead>
<tr>
<th>Low Maternal and Fetal Risks</th>
<th>High Maternal and Fetal Risks</th>
<th>High Maternal Risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic AS with a low mean outflow gradient (&lt;50 mm Hg); normal LV systolic function</td>
<td>Severe AS with or without symptoms</td>
<td>Ejection fraction &lt;40%</td>
</tr>
<tr>
<td>Aortic regurgitation, NYHA class I or II with normal LV function</td>
<td>Aortic regurgitation, NYHA class II, III, or IV</td>
<td>Previous heart failure</td>
</tr>
<tr>
<td>Mitral regurgitation, NYHA class I or II, with normal LV function</td>
<td>Mitral stenosis, NYHA class II, III, or IV</td>
<td>Previous stroke or transient ischemic attack</td>
</tr>
<tr>
<td>Mitral valve prolapse with none to moderate mitral regurgitation, normal LV function</td>
<td>Mitral regurgitation, NYHA class III or IV</td>
<td></td>
</tr>
<tr>
<td>Mild-to-moderate mitral stenosis, no pulmonary hypertension</td>
<td>Aortic or mitral valve disease with pulmonary hypertension</td>
<td></td>
</tr>
<tr>
<td>Mild-to-moderate pulmonary valve stenosis</td>
<td>Aortic or mitral valve disease with LV dysfunction</td>
<td></td>
</tr>
<tr>
<td>Maternal cyanosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reduced functional status, NYHA class III or IV</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AS indicates aortic stenosis; LV, left ventricular; and NYHA, New York Heart Association. Reprinted from Reimold and Rutherford with permission of the publisher. Copyright ©2003, Massachusetts Medical Society.
Dual-antiplatelet therapy with lose-dose aspirin and P2Y12 inhibitor such as clopidogrel is considered standard therapy after TAVR.44 There are no adequately controlled trials that have studied P2Y12 inhibitors during pregnancy or breast feeding, and hence, are not recommended.45

**Dr Kirker:** TAVR procedures are performed using several different arterial access approaches46 with percutaneous transfemoral access being the preferred approach. In a young healthy female patient, the iliofemoral anatomy was expected to be >6.0 mm and therefore able to accommodate the delivery sheaths and catheters. If the IVUS displayed a <6.0 mm iliofemoral access, the subclavian artery was planned as a backup access approach.

**Dr Hodson:** Annulus sizing was determined using the preoperative 3D TEE images shown in Figure 2. The aortic valve annulus diameter was measured to be 23.2×22.5 mm (Figure 2). After review of the case and TEE images with national and international experts, a plan was devised for a high implant to ensure sealing within the bicuspid anatomy.

**Dr Kirker:** The available valves at the time of the procedure were the Sapien XT (Edwards Life Sciences) and the CoreValve (Medtronic). The Sapien XT valve has the advantage of carrying a low risk of heart block and bradycardic rhythms necessitating a permanent pacemaker (5.3%) within 30 days postoperatively47 but presents a few limitations including a minimum access artery dimension of 6.5 mm and not being able to be repositioned.47 If the Sapien XT was used, the treatment team would require accurate dimensions of the aortic complex with a high confidence in the imaging modality used to obtain those dimensions. Our practice has been to rely primarily on gated CTA for accurate assessment of the aortic complex. Utilizing the Sapien XT would mean the team would only have one chance to choose the correct valve size. The CoreValve carries a higher risk of conduction abnormalities and higher risk (33.3%) of requiring a permanent pacemaker within 30 days postoperatively.48,49 The

---

**Table 4. WHO Classification of Maternal Cardiovascular Risk: Definitions**

<table>
<thead>
<tr>
<th>Risk Class</th>
<th>Risk of Pregnancy by Medical Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>No detectable increased risk of maternal mortality and no/mild increase in morbidity.</td>
</tr>
<tr>
<td>II</td>
<td>Small increased risk of maternal mortality or moderate increase in morbidity.</td>
</tr>
<tr>
<td>III</td>
<td>Significantly increased risk of maternal mortality or severe morbidity. Expert counseling required. If pregnancy is decided upon, intensive specialist cardiac and obstetric monitoring needed throughout pregnancy, childbirth, and the puerperium.</td>
</tr>
<tr>
<td>IV</td>
<td>Extremely high risk of maternal mortality or severe morbidity; pregnancy contraindicated. If pregnancy continues, care as for class III.</td>
</tr>
</tbody>
</table>

WHO indicates World Health Organization. Reprinted from Regitz-Zagrosek et al12 with permission of the publisher. Copyright ©2011, the European Society of Cardiology. Originally adapted from Thorne et al20 with permission of the publisher. Copyright ©2006, BMJ. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.

---

**Table 5. WHO Classification of Maternal Cardiovascular Risk by Cardiac Conditions**

<table>
<thead>
<tr>
<th>Risk Class</th>
<th>Cardiac Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Uncomplicated, small, or mild</td>
</tr>
<tr>
<td>II</td>
<td>Pulmonary stenosis</td>
</tr>
<tr>
<td>III</td>
<td>Patent ductus arteriosus</td>
</tr>
<tr>
<td>IV</td>
<td>Mitral valve prolapse</td>
</tr>
<tr>
<td>IV (pregnancy contraindicated)</td>
<td>Successfully repaired simple lesions (arterial or ventricular septal defect, patent ductus arteriosus, anomalous pulmonary venous drainage)</td>
</tr>
<tr>
<td>II</td>
<td>Atrial or ventricular ectopic beats, isolated</td>
</tr>
<tr>
<td>II–III (depending on individual)</td>
<td>Unoperated atrial or ventricular septal defect</td>
</tr>
<tr>
<td>III</td>
<td>Repaired Tetralogy of Fallot</td>
</tr>
<tr>
<td>III</td>
<td>Most arrhythmias</td>
</tr>
<tr>
<td>II–IV</td>
<td>Mild left ventricular impairment</td>
</tr>
<tr>
<td>III</td>
<td>Hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>III</td>
<td>Native or tissue valvular heart disease not considered WHO I or IV</td>
</tr>
<tr>
<td>III</td>
<td>Marfan syndrome without aortic dilation</td>
</tr>
<tr>
<td>III</td>
<td>Aorta &lt;45 mm in aortic disease associated with bicuspid aortic valve</td>
</tr>
<tr>
<td>III</td>
<td>Repaired coarctation</td>
</tr>
<tr>
<td>IV</td>
<td>Mechanical valve</td>
</tr>
<tr>
<td>III</td>
<td>Systemic right ventricle</td>
</tr>
<tr>
<td>IV</td>
<td>Fontan circulation</td>
</tr>
<tr>
<td>IV–V</td>
<td>Cyanotic heart disease (unrepaired)</td>
</tr>
<tr>
<td>III</td>
<td>Other complex congenital heart disease</td>
</tr>
<tr>
<td>IV</td>
<td>Aortic dilatation 40–45 mm in Marfan syndrome</td>
</tr>
<tr>
<td>IV</td>
<td>Aortic dilatation 45–50 mm in aortic disease associated with bicuspid aortic valve</td>
</tr>
<tr>
<td>IV</td>
<td>Pulmonary arterial hypertension of any cause</td>
</tr>
<tr>
<td>IV</td>
<td>Severe systemic ventricular dysfunction (LVEF &lt;30%, NYHA class III–IV)</td>
</tr>
<tr>
<td>IV</td>
<td>Previous peripartum cardiomyopathy with any residual impairment of left ventricular function</td>
</tr>
<tr>
<td>IV</td>
<td>Severe mitral stenosis, severe symptomatic aortic stenosis</td>
</tr>
<tr>
<td>IV</td>
<td>Marfan syndrome with aorta dilated &gt;45 mm</td>
</tr>
<tr>
<td>IV</td>
<td>Aortic dilatation &gt;50 mm in aortic disease associated with bicuspid aortic valve</td>
</tr>
<tr>
<td>IV</td>
<td>Native severe coarctation</td>
</tr>
</tbody>
</table>

LVEF indicates left ventricular ejection fraction; NYHA, New York Heart Association; and WHO, World Health Organization. Reprinted from Regitz-Zagrosek et al12 with permission of the publisher. Copyright ©2011, the European Society of Cardiology. Originally adapted from Thorne et al20 with permission of the publisher. Copyright ©2006, BMJ. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.
long-term durability of both of these valves are not fully known. For this case, the CoreValve seemed preferable to the Sapien XT because of the minimum requirement of a 6.0 mm access artery dimension for all valve sizes and the potential to be repositioned or removed if a different size was required. A self-expanding platform leads to more room for error in valve sizing. The long-term effects on the annulus and aortic root because of a younger patient’s more flexible, less calcified annulus and aortic root were considered. A 26-mm CoreValve was selected for this procedure because of the smaller sheath size requirement and the flexibility of valve sizing and positioning.

*Dr Swanson:* Even with the above planning and considerations, there were still several features about this procedure that were unknown, including the amount of calcification, tissue holding forces, long-term effects on soft aortic tissue, oversizing risks, need for a pacemaker, and fetal thyroid development. It is recognized that failure of the procedure, major injury to the thoracic aorta, abdominal aorta, or iliac arteries could potentially result in fetal demise. The uterine artery is a major sub-branch of the internal iliac artery. Vascular complications that would require rescue with an aortic occlusion balloon and no blood flow to the placenta, even transiently, would result in almost certain injury or death of the fetus. Occlusion of an internal iliac artery is generally well tolerated because of contralateral iliac collateral circulation. The TAVR delivery sheath may occlude the iliac artery during TAVR procedures, depending on sheath size and patient anatomy. Transient occlusion of one of the common iliac arteries during pregnancy could theoretically be tolerated without fetal injury. However, there is no extensive experience regarding fetal health with acute internal iliac occlusion. Because of ethical concerns, randomized trials will likely never be available to guide management of iliac injury during pregnancy. Emergency surgical rescue for aortic valve replacement, aortic root repair, and repair of aortic dissection was also discussed and would be executed as a last option to save the mother, with the understanding that fetal loss was likely.

Figure 2. Preoperative 3D transesophageal echocardiogram images. **A**, Aortic annulus diameter (Ao Ann diam; 23.2×22.5 mm) and annulus area (425 mm²). **B**, Aortic annulus diameter (23.6 mm) and left ventricular outflow tract diameter (LVOT; 21.2 mm). **C**, Sinotubular junction diameter (STJ diam; 24 mm). NCC indicates noncoronary cusp; and RCC, right-coronary cusp.
Procedure
The procedure was performed as planned employing general anesthesia at 22 weeks’ gestation. The patient was pretreated with aspirin 81 mg, and heparin was administered during the procedure. Removable lead sheeting (from a catheterization laboratory table shield) was placed on the procedure table underneath the patient providing shielding from above the umbilicus to below the mid-thigh. Removable lead was used for the event when emergency imaging of the abdomen and pelvis was required. In addition, standard gonadal shielding was positioned to further protect the uterus and fetus.

IVUS demonstrated a normal 7 to 8 mm iliofemoral anatomy (Figure 3). Only 3D TEE, fluoroscopy, and fluoro saves (no cineangiography) were used to assist in the positioning and deployment of the 26-mm CoreValve valve with a high implant. If necessary, the valve could have been sized up to 29 mm, which proved unnecessary because 26 mm was delivered successfully. A mild paravalvular leak was observed. A new left bundle branch block occurred, and a temporary pacing wire was placed. Radiation was limited to 10.3 minutes of fluoro time (at 7.5 frames per second), 101.3 mGy of cumulative fluoro time, 1325 cGycm² of dose–area product, and only 10.3 minutes of intraoperative IVUS were taken. Eighty-seven milliliters of iodixanol 240 of contrast was used.

Clinical Outcome
Immediately after the procedure, the fetal heart rate and maternal reported fetal activity were normal. Low-dose aspirin and low-dose heparin were administered after the procedure. The patient was discharged on postoperative day 5 on aspirin and low-dose heparin were administered after the procedure. The patient was discharged on postoperative day 5 on aspirin 81 mg, and heparin was administered during the procedure. Removable lead sheeting (from a catheterization laboratory table shield) was placed on the procedure table underneath the patient providing shielding from above the umbilicus to below the mid-thigh. Removable lead was used for the event when emergency imaging of the abdomen and pelvis was required. In addition, standard gonadal shielding was positioned to further protect the uterus and fetus.

IVUS demonstrated a normal 7 to 8 mm iliofemoral anatomy (Figure 3). Only 3D TEE, fluoroscopy, and fluoro saves (no cineangiography) were used to assist in the positioning and deployment of the 26-mm CoreValve valve with a high implant. If necessary, the valve could have been sized up to 29 mm, which proved unnecessary because 26 mm was delivered successfully. A mild paravalvular leak was observed. A new left bundle branch block occurred, and a temporary pacing wire was placed. Radiation was limited to 10.3 minutes of fluoro time (at 7.5 frames per second), 101.3 mGy of cumulative fluoro time, 1325 cGycm² of dose–area product, and only 10.3 minutes of intraoperative IVUS were taken. Eighty-seven milliliters of iodixanol 240 of contrast was used.

Conclusions
Symptomatic AS during pregnancy is a high-risk condition for both the mother and the fetus. A TAVR procedure was chosen because of the perceived high likelihood of success and low probability of complications to safely bridge both the mother and the fetus to delivery. In the interest of fetal safety and decreased maternal cancer risk, radiation and contrast exposure had to be minimized. High-quality preoperative and intraoperative 3D TEE and intraoperative IVUS were used. CTA and cineangiography were successfully avoided. Arguably, the most critical piece to the success of this procedure was the heart team evaluation and discussion. The heart team included nontraditional members such as radiation experts and perinatologists, and the team consulted with national and international experts to determine the best course of action for the mother and fetus. The anecdotal experience of this successful case leads us to suggest that TAVR should be researched as a possible low-risk option for the treatment of AS during pregnancy.

Disclosures
None.

References
Hodson et al  TAVR During Pregnancy

line for the management of patients with valvular heart disease: execu-


14. Gersony DR, McCloughlin MA, Jin Z, Gersony WM. The effect of beta-

15. Reimold SC, Rutherford JD. Clinical practice. Valvular heart dis-


18. Roeder HA, Kuller JA, Barker PC, James AH. Maternal valvular heart dis-


22. Roeder HA, Kuller JA, Barker PC, James AH. Maternal valvular heart dis-


thoracsur.2010.11.037.

26. Williams GM, Gott VL, Brawley RK, Schaufelberger M, Labs JD. Aortic disease asso-

27. John AS, Gurley F, Schaff HV, Warnes CA, Phillips SD, Arendt KW, Abel MD, Rose C, Connolly HM. Cardiopulmonary bypass dur-
thoracsur.2010.11.037.


31. McIvor RA. Percutaneous balloon aortic valvuloplasty during pregnant-


Key Words: aortic valve ▪ body mass index ▪ body surface area ▪ dizziness ▪ pregnancy
Transcatheter Aortic Valve Replacement During Pregnancy
Robert Hodson, Eric Kirker, Jeffrey Swanson, Craig Walsh, Ethan C. Korngold and Sarah Ramelli

Circ Cardiovasc Interv. 2016;9:
doi: 10.1161/CIRCINTERVENTIONS.116.004006
Circulation: Cardiovascular Interventions is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7640. Online ISSN: 1941-7632

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circinterventions.ahajournals.org/content/9/10/e004006

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Interventions can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Interventions is online at:
http://circinterventions.ahajournals.org//subscriptions/